Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Bendell Discusses Pembrolizumab in CRC

December 19th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

December 16th 2017

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.

Pembrolizumab Misses Endpoints in Phase III Gastric Cancer Trial

December 15th 2017

Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.

Dr. Kemeny on Liver-Directed Therapy for Metastatic CRC

December 14th 2017

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Expert Says Clinical Trials Are Essential for Progress in Metastatic CRC

December 13th 2017

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI Cancer

December 13th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy

December 13th 2017

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

Dr. Saltz Discusses Chemotherapy in Metastatic CRC

December 12th 2017

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.

Experts Describe Challenges of Targeting BRAF Mutations in CRC

December 12th 2017

Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.

Frontline Ramucirumab Does Not Improve OS in Gastric Cancer

December 9th 2017

Adding ramucirumab to cisplatin and capecitabine or 5-FU in the frontline setting did not improve overall survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results from the phase III RAINFALL trial.

Dr. Pant on the Third-Line Setting for Metastatic CRC

December 6th 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Dr. Pishvaian Discusses Progress in Pancreatic Cancer

December 5th 2017

Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.

Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

December 5th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

Dr. McCollum Discusses Immunotherapy in CRC

December 2nd 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Avelumab Falls Short in Phase III Gastric Cancer Trial

November 28th 2017

Avelumab did not improve overall survival compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III JAVELIN Gastric 300 trial.

Dr. Hendifar Discusses a 92-Gene Assay of NETs

November 28th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Role of Immunotherapy Being Defined in Colorectal Cancer

November 23rd 2017

A. David McCollum, MD, discusses the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.

OncLive and The Ruesch Center to Honor the Winners of The Luminary Awards in GI Cancers

November 23rd 2017

The inaugural Luminary Awards in GI Cancer, which will be hosted by OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, will honor Julie Fleshman, Daniel G. Haller, Henry T. Lynch, Frank McCormick and Andrew L. Warshaw for their dedication to the gastrointestinal cancers community.

Novel Treatments Emerging in Pancreatic Cancer

November 22nd 2017

Carlos Becerra, MD, discusses the current management and emerging therapies for patients with pancreatic cancer.